Different β -Blockers in STEMI and Primary PCI

Primary PCI Clinical Trial

Official title:
Different β -Blockers in Patients With ST-segment Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Status Not yet recruiting

Clinical Trial Summary

Carvedilol, target dose: 50 mg daily; Bisoprolol, target dose: 10 mg daily; Metoprolol tartrate, target dose: 150 mg daily; Metroprolol succinate, target dose: 200 mg daily

Clinical Trial Description

The investigators will investigate the efficacy and safety of different β -blockers, as well as heart rate variability, in STEMI patients undergoing primary PCI. ;

Study Design

Related Conditions & MeSH terms

Primary PCI

Clinical Trial Details

NCT number	NCT04221919
Study type	Interventional
Source	Qilu Hospital of Shandong University
Contact
Status	Not yet recruiting
Phase	N/A
Start date	January 2020
Completion date	January 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01136837` - The Prognostic Significance of a Fragmented QRS Complex After Primary Percutaneous Coronary Intervention	N/A
Recruiting	`NCT05605288` - Distal Versus Conventional Transradial Artery Access for Coronary Catheterization in Patients With STEMI	N/A
Active, not recruiting	`NCT05329155` - Early Administration of Heparin at FMC for PPCI of STEMI Patients	N/A
Withdrawn	`NCT03526367` - A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI	Phase 4
Recruiting	`NCT04034940` - Correlations Between Oxidative Stress Biomarkers, h-FABP and Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Undergoing Primary PCI	N/A